All In Biotech

Drug Trial Radar · NCT05179603

A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]

Phase 2 Non-randomized, Open-label, Multi-cohort, Multicenter Study Assessing the Clinical Benefit of SAR444245 (THOR-707) With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma

Last checked: Nov 20, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

14

Actual

Start

Dec 7, 2021

Primary completion

Sep 14, 2023

Study completion Sep 6, 2024

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jan 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2 multi-cohort, un-controlled, non-randomized, open-label, multi-center study that assessed the antitumor activity and safety of non-alpha interleukin (IL-2) SAR444245 with or without other anticancer therapies in participants aged 12 years and older with relapsed or refractory B cell lymphoma. This study was structured as a master protocol with separate sub studies designed to investigate the use of SAR444245 either with or without other anticancer therapies for the treatment of relapsed or refractory B cell lymphoma. Substudy 1-Cohort A aimed to establish safety and preliminary anti-tumor activity for non-alpha interleukin (IL-2) SAR444245 combined with the anti-PD1 antibody, pembrolizumab in trial participants with classic Hodgkin lymphoma (cHL) who are anti-PD-(L)1-naive and have received at least 2 or 3 lines of systemic therapy. Substudy 3-Cohort C1 aims to establish safety and preliminary anti-tumor activity for SAR444245 as monotherapy in trial participants with diffuse large B-cell lymphoma (DLBCL). Trial participants in this study must have received at least 2 lines of systemic therapy and have either stable or progressive disease 1-3 months post Health Authority approved Chimeric Antigen Receptor T-cell (CAR-T) treatment when given as last systemic treatment prior to study enrollment.

Conditions

  • Classic Hodgkin Lymphoma
  • Diffuse Large B-cell Lymphoma

Interventions

  • THOR-707Drug

    Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion

  • PembrolizumabDrug

    Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Response Rate (CRR)Time frame: From first dose of study treatment administration (Day 1) up to approximately 21 months

Locations

8 sites in 3 countries. Site status is shown where the registry gives one.

  • Investigational Site Number : 0320005

    CABA, Buenos Aires, Argentina

  • Investigational Site Number : 1520001

    Temuco, Chile

  • Investigational Site Number : 1520003

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520002

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520004

    Viña del Mar, Valparaiso, Chile

  • Investigational Site Number : 7240002

    Barcelona, Barcelona [Barcelona], Spain

  • Investigational Site Number : 7240001

    L'Hospitalet de Llobregat, Barcelona [Barcelona], Spain

  • Investigational Site Number : 7240004

    Madrid / Madrid, Madrid, Comunidad de, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.